Prokinectics for dyspepsia; SGLT2 inhibitors; acute gastroenteritis; combination probiotics… Debbie Rigby rounds up the latest in research news
A Cochrane review provided no support for use of prokinetics for the treatment of functional dyspepsia due to low quality evidence. There was uncertainty as to which of the individual prokinetic drugs is the most effective as well as whether prokinetics can improve quality of life. Apart from cisapride, prokinetics are well‐tolerated.
Cochrane Database of Systematic Reviews 2018, Issue 10.
A large cohort study has shown that use of SGLT2 inhibitors is associated with an increased risk of lower limb amputation and diabetic ketoacidosis compared with GLP1 receptor agonists. There was no increased risk compared to GLP1 receptor agonists for bone fracture, acute kidney injury, serious UTI, VTE or acute pancreatitis.
A prospective, randomized, double-blind trial involving children 3 months to 4 years of age with acute gastroenteritis has shown no better outcomes than placebo with a 5-day course of L. rhamnosus GG. A dose of 1 x 1010 CFU twice daily resulted in no significant differences in duration of diarrhoea, duration of vomiting or day-care absenteeism compared to placebo.
N Engl J Med 2018; 379:2002-2014.
A randomized, double-blind trial involving 886 children 3 to 48 months of age with gastroenteritis has shown probiotics do not prevent the development of moderate-to-severe gastroenteritis. Participants received a 5-day course of a combination probiotic product containing Lactobacillus rhamnosus R0011 and L. helveticus R0052, at a dose of 4.0×109 colony-forming units twice daily or placebo.
N Engl J Med 2018; 379:2015-2026.